5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

Author:

Hamid Omid1,Robert Caroline2,Daud Adil3,Hodi F. Stephen4,Hwu Wen-Jen5,Kefford Richard6,Wolchok Jedd D.7,Hersey Peter8,Joseph Richard Wayne9,Weber Jeffrey S.10,Dronca Roxana Stefania11,Mitchell Tara C.12,Patnaik Amita13,Zarour Hassane M.14,Joshua Anthony M.15,Jensen Erin16,Ibrahim Nageatte16,Ahsan Sama16,Ribas Antoni17

Affiliation:

1. The Angeles Clinic and Research Institute, Los Angeles, CA;

2. Gustave Roussy, Villejuif, France;

3. University of California, San Francisco, San Francisco, CA;

4. Dana-Farber Cancer Institute, Boston, MA;

5. The University of Texas MD Anderson Cancer Center, Houston, TX;

6. Westmead Hospital and Melanoma Institute, Macquarie Park, Australia;

7. Memorial Sloan Kettering Cancer Center, New York, NY;

8. Centenary Institute, University of Sydney, Sydney, Australia;

9. Mayo Clinic Cancer Center – Florida, Jacksonville, FL;

10. Perlmutter Cancer Center, NYU Langone Health, New York, NY;

11. Mayo Clinic, Rochester, MN;

12. University of Pennsylvania, Philadelphia, PA;

13. South Texas Accelerated Research Therapeutics, San Antonio, TX;

14. University of Pittsburgh Cancer Institute, Pittsburgh, PA;

15. UHN Princess Margaret Cancer Centre, Toronto, ON, Canada;

16. Merck & Co., Inc., Kenilworth, NJ;

17. University of California, Los Angeles, Los Angeles, CA;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3